BI Asset Management Fondsmaeglerselskab A S Has $4.90 Million Holdings in Hims & Hers Health, Inc. $HIMS

BI Asset Management Fondsmaeglerselskab A S raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 40.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 151,041 shares of the company’s stock after purchasing an additional 43,826 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Hims & Hers Health were worth $4,904,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC boosted its position in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. Finally, Entrust Financial LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter worth $47,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider owned 8,752 shares in the company, valued at $216,086.88. This represents a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 212,807 shares of company stock worth $5,473,644. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $26.25 on Monday. The firm’s fifty day simple moving average is $24.61 and its two-hundred day simple moving average is $27.02. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $6.08 billion, a P/E ratio of -291.71, a price-to-earnings-growth ratio of 49.14 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the company earned $0.20 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HIMS shares. JPMorgan Chase & Co. cut their price objective on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Leerink Partners raised their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research note on Monday, March 16th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.